Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring

• Águeda Molinos-Quintana,
• Anna Alonso-Saladrigues,
• Blanca Herrero,
• Teresa Caballero-Velázquez,
• Víctor Galán-Gómez,
• Melissa Panesso,
• Montserrat Torrebadell,
• Javier Delgado-Serrano,
• Concepción Pérez de Soto,
• Anna Faura,
• Berta González-Martínez,
• Ana Castillo-Robleda,
• Cristina Diaz-de-Heredia,
• Antonio Pérez-Martínez,
• José María Pérez-Hurtado,
• Susana Rives,
• Susana Rives,
• José Antonio Pérez-Simón

Affiliations

Águeda Molinos-Quintana

Pediatric Unit, Department of Hematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain

Anna Alonso-Saladrigues

CAR T-cell Unit. Leukemia and Lymphoma Department. Pediatric Cancer Center Barcelona (PCCB). Hospital Sant Joan de Déu de Barcelona, Barcelona, Spain

Blanca Herrero

Pediatric Hemato-Oncology Department, Peditric University Hospital del Niño Jesús, Madrid, Spain

Teresa Caballero-Velázquez

Department of Hematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain

Víctor Galán-Gómez

Pediatric Hemato-Oncology Department, University Hospital La Paz, Institute for Health Research (IdiPAZ), Universidad Autónoma de Madrid, Madrid, Spain

Melissa Panesso

Division of Pediatric Hematology and Oncology, Hospital Universitari Vall d’Hebron, Vall d’Hebron Research Institute (VHIR), Barcelona, Spain

Montserrat Torrebadell

CAR T-cell Unit. Leukemia and Lymphoma Department. Pediatric Cancer Center Barcelona (PCCB). Hospital Sant Joan de Déu de Barcelona, Barcelona, Spain

Javier Delgado-Serrano

Department of Hematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain

Concepción Pérez de Soto

Pediatric Unit, Department of Hematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain

Anna Faura

CAR T-cell Unit. Leukemia and Lymphoma Department. Pediatric Cancer Center Barcelona (PCCB). Hospital Sant Joan de Déu de Barcelona, Barcelona, Spain

Berta González-Martínez

Pediatric Hemato-Oncology Department, University Hospital La Paz, Institute for Health Research (IdiPAZ), Universidad Autónoma de Madrid, Madrid, Spain

Ana Castillo-Robleda

Pediatric Hemato-Oncology Department, Peditric University Hospital del Niño Jesús, Madrid, Spain

Cristina Diaz-de-Heredia

Division of Pediatric Hematology and Oncology, Hospital Universitari Vall d’Hebron, Vall d’Hebron Research Institute (VHIR), Barcelona, Spain

Antonio Pérez-Martínez

Pediatric Hemato-Oncology Department, University Hospital La Paz, Institute for Health Research (IdiPAZ), Universidad Autónoma de Madrid, Madrid, Spain

José María Pérez-Hurtado

Pediatric Unit, Department of Hematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain

Susana Rives

Pediatric Cancer Center Barcelona (PCCB), Institut de Recerca Sant Joan de Déu, Leukemia and Pediatric Hematology Disorders, Developmental Tumors Biology Group, Barcelona, Spain

Susana Rives

Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red De Enfermedades Raras (CIBERER), Madrid, Spain

José Antonio Pérez-Simón

Department of Hematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain